Compare SQFT & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SQFT | PRPO |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 32.4M |
| IPO Year | 2020 | N/A |
| Metric | SQFT | PRPO |
|---|---|---|
| Price | $3.12 | $23.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 85.4K | 8.8K |
| Earning Date | 02-11-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $17,525,365.00 | ★ $22,800,000.00 |
| Revenue This Year | $23.63 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 30.95 |
| 52 Week Low | $3.04 | $3.90 |
| 52 Week High | $23.00 | $28.50 |
| Indicator | SQFT | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 32.35 | 53.04 |
| Support Level | $3.04 | $22.10 |
| Resistance Level | $3.37 | $25.03 |
| Average True Range (ATR) | 0.29 | 1.20 |
| MACD | -0.03 | -0.26 |
| Stochastic Oscillator | 12.21 | 50.76 |
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.